Paper Details

  1. Home
  2. Paper Details

Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.

Author: AndersonAshley, IosifescuDan V, JacobsonMark, JonesAmanda, TabuteauHerriot

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase 2 trial evaluated the efficacy and safety of dextromethorphan-bupropion, an oral NMDA receptor antagonist and sigma-1 receptor agonist, for the treatment of major depressive disorder. The study explores the potential of this medication in addressing altered glutamatergic neurotransmission, a key factor in the pathogenesis of depression.
Paper Details　
Original Abstract of the Article :
Altered glutamatergic neurotransmission is implicated in the pathogenesis of major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist, which utilizes inhibition of CYP2D6 to increase its bioavailability. This phase 2 trial assess...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1176/appi.ajp.21080800

データ提供：米国国立医学図書館（NLM）

AXS-05 for Major Depressive Disorder: A Phase 2 Trial

This phase 2 trial evaluates the efficacy and safety of AXS-05 (dextromethorphan-bupropion) in the treatment of major depressive disorder. It's like venturing into a new territory in the desert of mental health research, seeking innovative treatments for a challenging condition. The study explores the potential of AXS-05, an NMDA receptor antagonist and sigma-1 receptor agonist, to provide relief from depressive symptoms. The researchers hope to shed light on the potential of this novel drug in treating depression, offering a potential new avenue for addressing this debilitating condition.

AXS-05: A Potential Oasis in the Depression Desert

The study's findings hold promise for individuals struggling with major depressive disorder. It's like discovering a potential new oasis in the vast and often desolate desert of depression. The researchers' work explores the potential of AXS-05, a novel drug targeting specific receptors in the brain, to provide relief from depressive symptoms. This study offers hope for a new treatment option for this challenging condition.

Navigating the Desert of Depression

This research highlights the ongoing efforts to develop new and effective treatments for depression. It's like searching for new pathways through the vast and often challenging desert of depression. The study's findings offer hope for a potential new treatment option, emphasizing the importance of continued research and innovation in the search for effective solutions for mental health disorders.

Dr.Camel's Conclusion

This phase 2 trial offers a glimpse into the potential of AXS-05 for treating major depressive disorder. It's like finding a promising oasis in the vast desert of mental health research. The study underscores the importance of exploring new avenues for addressing this challenging condition and offers hope for a potential new treatment option for those struggling with depression.

Date :
  1. Date Completed 2022-07-04
  2. Date Revised 2022-07-14
Further Info :

Pubmed ID

35582785

DOI: Digital Object Identifier

10.1176/appi.ajp.21080800

Related Literature

Article Analysis
・Effects of dextromethorphan and bupropion
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.